Abstract Library

#4658 The nutritional status worsens over 5 years in patients with gastroenteropancreatic neuroendocrine tumours on treatment with somatostatin analogues

Introduction: Malnutrition is common in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) treated with monthly somatostatin analogues (SSAs). Ideally all malnourished patients are offered nutritional support. However, clinical guidelines and data on the development and progression of malnutrition is lacking.

Conference:

Presenting Author: Clement D

Authors: Soran V, Srirajaskanthan R, Cananea E, Martin W, Minott S,

Keywords: gastroenteropancreatic neuroendocrine tumour, malnutrition, somatostatin analogue,

#4532 Gender differences in patients with medullary thyroid cancer (MTC): A single-centre experience

Introduction: Medullary thyroid cancer (MTC) accounts for 3-5% of thyroid tumours. It can be sporadic or associated with genetic syndrome. The role of gender in the MTC isn’t clarified.

Conference:

Presenting Author:

Authors: Cannavale G, Minotta R, Liccardi A, Benevento E, Di Iasi G,

Keywords: MTC, gender difference, gender medicine,

#4503 Duodenopancreatic neuroendocrine tumour in MEN1: Gender difference and survival rates

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is the most common inherited syndrome associated with NET development and metastatic duodenal-pancreatic (DP) NET is the main cause of death.

Conference:

Presenting Author: Liccardi A

Authors: Liccardi A, Roberto M, Cannavale G, Benevento E, Di Iasi G,

Keywords: Multiple endocrine neoplasia type 1, neuroendocrine tumour, gender difference, survival,

#4448 Statins and somatostatin analogues in gastroenteropancreatic neuroendocrine tumours (GEP-NET): Impact on overall survival

Introduction: Gastroenteropancreatic neuroendocrine tumours (GEP-NET) are rare neoplasia with unclear risk factor influencing their development and survival. Statins appear to enhance antiproliferative effect of some chemotherapies in other cancers, but their effect in GEP-NET treated with somatostatin analogues (SSA) are largely unknown.

Conference:

Presenting Author: Benevento E

Authors: Benevento E, Liccardi A, Minotta R, Cannavale G, Di Iasi G,

Keywords: statins, neuroendocrine tumour, gastroenteropancreatic, overall survival, somatostatin analogue,

#4408 Metabolic syndrome (MetS) and metastatic disease in patients with sporadic small intestine neuroendocrine tumour (SiNET)

Introduction: Small intestine neuroendocrine tumours (SiNETs) are rare neoplasms in which the identification of new risk factors is essential. Metabolic syndrome (MetS) is a cluster of risk factors that lead to increased mortality, especially by cardiovascular (CV) causes. MetS diagnosis is obtained with International Diabetes Federation (IDF) 2005 criteria.

Conference:

Presenting Author: Minotta R

Authors: Minotta R, Liccardi A, Cannavale G, Benevento E, Di Iasi G,

Keywords: small intestine neuroendocrine tumour, metabolic syndrome, metastatic disease, survival, progression, metastasis,